Shree Ganesh Remedies Ltd
Shree Ganesh Remedies Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #81 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
FY’26 is considered a year of consolidation and capability building; sales expected to be similar to FY’25. FY’26 is a consolidation year focused on capability building, with no major growth guidance for this year.
From Shree Ganesh Remedies Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY’26 is considered a year of consolidation and capability building; sales expected to be similar to FY’25.
- Commercial volumes for new molecules are under evaluation; clarity on FY’27 growth is currently uncertain.
- Anticipated initial volume pickup for new products expected by Q2 FY’27.
- Post FY’27, growth is linked to commercial scale-up of innovator molecules and specialty chemicals.
- New agrochemical product expected to reach peak sales by 2029-2030.
- Expansion projects (Block 7 and Dahej plant) targeted to enable future growth with higher volume products.
- Transition from generic to innovator molecules over 3-4 years expected to contribute significantly to revenue.
2 more points from Shree Ganesh Remedies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Shree Ganesh Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Shree Ganesh Remedies Limited is undertaking expansion and capacity-building initiatives.
- Recently commissioned Block 8 in Unit 1, with capacity utilization expected to reach 50% to 60% by year-end.
- Block 7 is under construction with commercial production planned for the second half of FY’27.
- Expansion is taking place on newly acquired adjoining property (former Jaiswal Pharma Chem).
- Dahej plant expansion planned with a timeline of about two years from now, focusing on bulkier specialty commodity or high-volume products developed collaboratively with customers.
- New pilot facility commissioning is in final stages and expected operational by Q4 FY’26.
2 more points from Shree Ganesh Remedies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shree Ganesh Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is in a consolidation phase for FY’26 with sales expected to be similar to last year.
- New product trials and approvals are ongoing, with initial volumes from new projects anticipated by Q2 FY’27.
- Supply for some innovator molecules will start before generic launch, with commercial scaling expected in 3-4 years.
- Agrochemical projects have received client approvals; bulk purchasing expected to start in 2027 with peak sales around 2029-2030.
2 more points from Shree Ganesh Remedies Ltd's call on order book
Create a free account to keep reading this call
Shree Ganesh Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹33 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shree Ganesh Remedies Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Shree Ganesh Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Shree Ganesh Remedies Ltd Q2 FY26 results?
FY’26 is considered a year of consolidation and capability building; sales expected to be similar to FY’25. FY’26 is a consolidation year focused on capability building, with no major growth guidance for this year.
What is Shree Ganesh Remedies Ltd share price analysis?
Shree Ganesh Remedies Ltd currently shows a neutral. The stock trades at a P/E of 40.8 with a market cap of ₹630 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shree Ganesh Remedies Ltd planning capital expenditure?
Shree Ganesh Remedies Limited is undertaking expansion and capacity-building initiatives.
Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.